Literature DB >> 26501768

Unmanipulated haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in a patient with paroxysmal nocturnal hemoglobinuria and secondary aplastic anemia.

M Sarmiento1, P A Ramírez1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26501768     DOI： 10.1038/bmt.2015.251

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  11 in total

1.  Paroxysmal nocturnal hemoglobinuria and eculizumab.

Authors:  Lucio Luzzatto; Antonio Maria Risitano; Rosario Notaro
Journal:  Haematologica       Date:  2010-04       Impact factor: 9.941

2.  Haploidentical hematopoietic SCT for acquired severe aplastic anemia using post-transplant high-dose CY.

Authors:  N Gupta; D Choudhary; S K Sharma; V Khandelwal; M Dhamija
Journal:  Bone Marrow Transplant       Date:  2014-10-06       Impact factor: 5.483

3.  Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study.

Authors:  Yu Wang; Qi-Fa Liu; Lan-Ping Xu; Kai-Yan Liu; Xiao-Hui Zhang; Xiao Ma; Zhi-Ping Fan; De-Pei Wu; Xiao-Jun Huang
Journal:  Blood       Date:  2015-05-04       Impact factor: 22.113

Review 4.  Paroxysmal nocturnal hemoglobinuria.

Authors:  Robert A Brodsky
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

5.  Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.

Authors:  Stefan O Ciurea; Mei-Jie Zhang; Andrea A Bacigalupo; Asad Bashey; Frederick R Appelbaum; Omar S Aljitawi; Philippe Armand; Joseph H Antin; Junfang Chen; Steven M Devine; Daniel H Fowler; Leo Luznik; Ryotaro Nakamura; Paul V O'Donnell; Miguel-Angel Perales; Sai Ravi Pingali; David L Porter; Marcie R Riches; Olle T H Ringdén; Vanderson Rocha; Ravi Vij; Daniel J Weisdorf; Richard E Champlin; Mary M Horowitz; Ephraim J Fuchs; Mary Eapen
Journal:  Blood       Date:  2015-06-30       Impact factor: 22.113

6.  Haploidentical BMT and post-transplant Cy for severe aplastic anemia: a multicenter retrospective study.

Authors:  I Esteves; C Bonfim; R Pasquini; V Funke; N F Pereira; V Rocha; Y Novis; C Arrais; V Colturato; M P de Souza; M Torres; J F Fernandes; F R Kerbauy; A A F Ribeiro; F P S Santos; N Hamerschlak
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

7.  Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival.

Authors:  Richard J Kelly; Anita Hill; Louise M Arnold; Gemma L Brooksbank; Stephen J Richards; Matthew Cullen; Lindsay D Mitchell; Dena R Cohen; Walter M Gregory; Peter Hillmen
Journal:  Blood       Date:  2011-04-01       Impact factor: 22.113

8.  Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in nonmalignant hematologic diseases.

Authors:  R A Brodsky; L Luznik; J Bolaños-Meade; M S Leffell; R J Jones; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-07-14       Impact factor: 5.483

9.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

Authors:  Leo Luznik; Paul V O'Donnell; Heather J Symons; Allen R Chen; M Susan Leffell; Marianna Zahurak; Ted A Gooley; Steve Piantadosi; Michele Kaup; Richard F Ambinder; Carol Ann Huff; William Matsui; Javier Bolaños-Meade; Ivan Borrello; Jonathan D Powell; Elizabeth Harrington; Sandy Warnock; Mary Flowers; Robert A Brodsky; Brenda M Sandmaier; Rainer F Storb; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

10.  Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia.

Authors:  Jennifer Clay; Austin G Kulasekararaj; Victoria Potter; Francesco Grimaldi; Donal McLornan; Kavita Raj; Hugues de Lavallade; Michelle Kenyon; Antonio Pagliuca; Ghulam J Mufti; Judith C W Marsh
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742
View more
  4 in total

1.  Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide.

Authors:  Amy E DeZern; Marianna L Zahurak; Heather J Symons; Kenneth R Cooke; Gary L Rosner; Douglas E Gladstone; Carol Ann Huff; Lode J Swinnen; Philip Imus; Ivan Borrello; Nina Wagner-Johnston; Richard F Ambinder; Leo Luznik; Javier Bolaños-Meade; Ephraim J Fuchs; Richard J Jones; Robert A Brodsky
Journal:  Blood Adv       Date:  2020-04-28

2.  Alternative Donor Transplantation with High-Dose Post-Transplantation Cyclophosphamide for Refractory Severe Aplastic Anemia.

Authors:  Amy E DeZern; Marianna Zahurak; Heather Symons; Kenneth Cooke; Richard J Jones; Robert A Brodsky
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-21       Impact factor: 5.742

3.  Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.

Authors:  Amy E DeZern; Mary Eapen; Juan Wu; Julie-An Talano; Melhem Solh; Blachy J Dávila Saldaña; Chatchada Karanes; Mitchell E Horwitz; Kanwaldeep Mallhi; Sally Arai; Nosha Farhadfar; Elizabeth Hexner; Peter Westervelt; Joseph H Antin; H Joachim Deeg; Eric Leifer; Robert A Brodsky; Brent R Logan; Mary M Horowitz; Richard J Jones; Michael A Pulsipher
Journal:  Lancet Haematol       Date:  2022-07-27       Impact factor: 30.153

Review 4.  Haploidentical Donor Bone Marrow Transplantation for Severe Aplastic Anemia.

Authors:  Amy E DeZern; Robert A Brodsky
Journal:  Hematol Oncol Clin North Am       Date:  2018-05-28       Impact factor: 3.722
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.